Regeneron Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1988-01-01
- Employees
- 13.4K
- Market Cap
- $132.4B
- Website
- http://www.regeneron.com
- Introduction
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
Early Switch Therapy to Atezolizumab After Vemurafenib/Cobimetinib Run-in Improves OS
Early switch to atezolizumab after vemurafenib plus cobimetinib in BRAF V600-positive melanoma showed improved OS at 4 and 5 years in the ImmunoCobiVem trial, but not statistically significant. Rapid progression after switch to immune checkpoint inhibition was observed in some patients.
Long-Term KEYNOTE-006 Data Support Pembrolizumab as SOC in Advanced Melanoma
Pembrolizumab (Keytruda) showed improved survival over ipilimumab (Yervoy) in stage III/IV melanoma patients, with 10-year OS rates of 34% vs 23.6% and MSS rates of 45.2% vs 31.3%. Pembrolizumab's median OS was 32.7 months vs 15.9 months for ipilimumab, and median modified PFS was 9.4 months vs 3.8 months. Patients who responded well to initial pembrolizumab treatment had significant long-term benefits, with 80% OS rate after 94 weeks of treatment. These results support pembrolizumab as a standard care for advanced melanoma.
Related Clinical Trials:
Dupilumab (Dupixent) becomes first FDA-approved drug for adolescent CRSwNP
FDA expands approval of dupilumab (Dupixent) to treat chronic rhinosinusitis with nasal polyps (CRSwNP) in adolescents aged 12-17, based on clinical trial data showing significant improvements in nasal congestion, polyp size, and sense of smell, reducing need for systemic corticosteroids or surgery.
Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer
R.A.S., M.S.T., C.Y., R.N., H.S.R., M.D., A.J.C., E.S.-R., J.C.B., C.O., K.K., A.D.E., C.V., N.W., K.S.A., A.S.C., C.F., C.I., A.T., J.T., K.Y., L.H., K.G., F.M.H., T.S., A.L.A., P.B., P.N., G.L.H., W.F.S., J.P., P.P., A.D.M., D.Y., L.J.v.V., N.M.H., L.J.E. report various institutional research funding, advisory roles, consultancy, honoraria, patents, and stock ownership.
FDA Approves Dupilumab Label Expansion with Indication for CRSwNP in Adolescents
The FDA approved dupilumab (Dupixent) as add-on maintenance therapy for adolescents aged 12-17 with inadequately controlled chronic rhinosinusitis with nasal polyposis (CRSwNP), marking the first biologic treatment for this age group. Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 pathways, significantly improves symptoms and reduces the need for systemic corticosteroids or surgery, with a safety profile consistent with its known effects.
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor
Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents
Dupixent approved by FDA for adolescents aged 12-17 with inadequately controlled CRSwNP, offering an alternative to standard treatments that often fail to control symptoms and prevent nasal polyp recurrence.
Dupixent Approved in the US as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps
FDA approves Dupixent for adolescents aged 12-17 with chronic rhinosinusitis with nasal polyps, expanding its initial 2019 approval for adults.
FDA Approves Dupilumab for Adolescents with Chronic Rhinosinusitis with Nasal Polyps
The FDA approved dupilumab (Dupixent) as add-on maintenance therapy for 12-17-year-olds with chronic rhinosinusitis with nasal polyposis (CRSwNP), expanding its age range following the 2019 approval for adults. Dupilumab, a monoclonal antibody targeting IL-4 and IL-13 pathways, is not an immunosuppressant. This approval follows positive phase 3 data and long-term efficacy findings in CRSwNP patients.
© Copyright 2025. All Rights Reserved by MedPath